-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26

Benzinga·11/18/2026 12:36:04
Diffusion vocale
Stifel analyst Jonathan Block upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from $22 to $26.